

Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study

NCT07410039

Status	RECRUITING
Phase	Phase 4
Sponsor	Chinese PLA General Hospital
Enrollment	200 participants

Key Eligibility Criteria

Inclusion (7)

- Age: 18 - 65 years old, gender not restricted.
- Patients who meet the diagnostic criteria for NMOSD as set by the International Panel for NMO Diagnosis (IPND) in 2015, and have positive serum AQP4-IgG (by CBA method or live cell method).
- Acute phase of NMOSD-ON, defined as new or worsening optic nerve dysfunction (visual acuity decline accompanied or not by eye pain and visual field defect), with an onset duration of ≤ 21 days, and clear evidence of new or recurrent optic nerve damage on imaging (new or expanded T2WI lesions, with enhancement); the best corrected visual acuity (BCVA) of the affected eye during the acute phase of NMOSD-ON (if both eyes are affected simultaneously, the worse eye is considered) drops from above 0.3 to ≤ 0.1 .
- Acute phase of NMOSD-TM, defined as new or worsening spinal cord dysfunction (limb weakness or numbness, accompanied or not by urinary and defecation disorders), with an onset duration of ≤ 21 days, and clear evidence of new or recurrent spinal cord damage on imaging (new or expanded T2WI lesions, with enhancement); the EDSS score during the acute phase of NMOSD-TM increases from ≤ 4.0 to ≥ 6.0 .
- Clinical onset and recurrence determination requires unanimous judgment by each center and the center committee (an independent group of 3 people).

... and 2 more (see full listing online)

Exclusion (15)

- Damage to the optic nerve or spinal cord caused by other non-NMOSD-related factors.
- Abnormal laboratory indicators that need to be excluded from the subjects include, but are not limited to the following indicators:
- Neutrophils $< 1.5 \times 10^9/L$, Hemoglobin $< 90g/L$, Platelet count $< 75 \times 10^9/L$; Serum creatinine $> 1.5 \times ULN$, Total bilirubin $> 1.5 \times ULN$, Aspartate aminotransferase (AST) $> 1.5 \times ULN$, Alanine aminotransferase (ALT) $> 1.5 \times ULN$, Alkaline phosphatase $> 2 \times ULN$ HbA1c $> 8\%$ (for diabetic patients); GFR $< 60 mL/minute/1.73m^2$.
- Pregnant or lactating women, as well as those planning to become pregnant during the study period.
- Those who have received PE/IA/IVIG/FcRn/B-cell depletion/C5/IL-6 treatment within 1 month before enrollment.

... and 10 more (see full listing online)

Locations (1 total)

the First Medical Center of Chinese PLA General Hospital, Beijing, China

<https://clinicaltrials.gov/study/NCT07410039>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.